2/22/2007

Genentech is urging doctors to use its Lucentis drug to treat age-related macular degeneration, but some doctors choose to use Genentech's cancer drug Avastin instead, even though Avastin is not FDA-approved to treat eye problems. The federal government is stepping in by conducting an NIH-funded comparison trial of the two biotech drugs. BIO argues that the NIH should study cutting-edge science rather than spend money to compare two approved drugs.

Related Summaries